Recently, China Biodiversity Conservation and Green Development Foundation (CBCGDF) read an article “Despite the headlines, China’s Government still promotes pangolin scales in traditional medicines” (https://eia-international.org/news/despite-the-headlines-chinas-government-still-promotes-pangolin-scales-in-traditional-medicines/). What is CBCGDF’s comment on pangolin’s delisting from Pharmacopoeia? Does it mean that the medicinal pangolin use will continue to be promoted and legalized as mentioned in the EIA’s article?
CBCGDF Pangolin Working Group pays close attention to this article. While praising the continuous efforts from international colleagues on this issue, Dr. Zhou Jinfeng, the Secretary-General of CBCGDF also leads the Pangolin Working Group, has expressed his disagreement on the EIA article.
Dr. Zhou pointed out: “The removal has made fundamental progress and brings significant changes. The removal of pangolin from Chinese pharmacopoeia is an important step in the protection of pangolin in China.
As important progress to the protection of endangered wildlife in our country and positive influences from the Decision is undeniable. We predict that (as you will see) the Removal from Pharmacopoeia will significantly reduce the amount of pangolin smuggling this year. You’ll see the results, which will prove that we are right.
Of course, they’re still problems, like the patent prescriptions as EIA mentioned. We have realized this problem. The CBCGDF will continue to work actively, to promote communication between multi-stakeholders, and to bring lawsuits against relevant producers/users, so that the problem of “using pangolin scales as medicine” will be effectively stopped in the actual production process.
Original Chinese article:
By / Linda